ArticleFuture medicinal chemistry2017
Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus.
Article in Future medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Article
- Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity.Nature communications · 2026Article
- In Vivo Antimicrobial Activity of Nisin Z AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Synthetic Cation Transporters Eradicate Drug-ResistantJACS Au · 2025Article
- The VirtuousAntibiotics (Basel, Switzerland) · 2023Review
- Vanadate inhibits Feo-mediated iron transport in Vibrio cholerae.Metallomics : integrated biometal science · 2021Article
- Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening.Journal of microbiology (Seoul, Korea) · 2020Review
- Effect of new carbonyl cyanide aromatic hydrazones on biofilm inhibition against methicillin resistantRSC advances · 2020Article
- New solvent options forVirulence · 2019Article
- Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing.Virulence · 2019Review
- The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-ResistantFrontiers in microbiology · 2019Article
- Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.Microbial drug resistance (Larchmont, N.Y.) · 2018Article
- Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
aimCompound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one (compound 1) was identified as a hit against methicillin-resistant Staphylococcus aureus (MRSA) strain MW2. METHODS &
resultsThe MIC of compound 1 against MRSA was 4 μg/ml. The compound showed enhanced activity at acidic pH by lowering bacterial intracellular pH and exhibited no lysis of human red blood cells at up to 64 μg/ml and its IC
conclusionCompound 1 is a protonophore with potent in vitro and in vivo activity against MRSA and no toxicity in mammalian cells up to 8 μg/ml that warrants further investigation as a novel antibacterial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.